fr
Article scientifique
Accès libre
Anglais

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis

Publié dansJournal of Hepatology, vol. 72, no. 6, p. 1112-1121
Date de publication2020
Résumé

Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1-6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. A systematic review and meta-analysis of the real-world effectiveness and safety of glecaprevir/pibrentasvir were undertaken.

Citation (format ISO)
LAMPERTICO, Pietro et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis. In: Journal of Hepatology, 2020, vol. 72, n° 6, p. 1112–1121. doi: 10.1016/j.jhep.2020.01.025
Fichiers principaux (1)
Article (Published version)
Identifiants
ISSN du journal0168-8278
175vues
110téléchargements

Informations techniques

Création16.10.2020 15:02:00
Première validation16.10.2020 15:02:00
Heure de mise à jour15.03.2023 22:57:01
Changement de statut15.03.2023 22:57:00
Dernière indexation12.02.2024 13:20:07
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack